banter and General Discussion, page-10601

Hi @ddwn,

as I've mentioned elsewhere, I don't share the view that 'the CEO has managed the funding badly'. Of course, partly this is because I don't have access to the factual matrix in which funding/ financing decisions were made, but this is the same for all listed public entities - I've learned over the years not to judge when I don't have all, or even most, of the facts (NB: remember how many 'good' & virtuous Australian people at the time thought Lindy Chamberlain was a 'murdering killer mum' & absolutely belonged in deepest, darkest hellish gaol - right up until baby Azaria's jacket was found near a dingo lair 3 years afterward? It took 32 years for a coroner to officially change the report - go figure).

And partly it's due to the business model under which a small non-US startup biotech has been able to keep its head above water while many other big name biotechs went under during and after COVID-19, and still are going under. Especially in the cellular therapy space.

Where is ATHX? https://www.fiercebiotech.com/biotech/athersys-files-bankruptcy-sells-assets-healios-wake-roke-cell-therapys-struggles

Where is GMDA.OQ? https://www.fiercebiotech.com/biotech/unable-find-partner-stem-cell-therapy-gamida-accepts-sale-investment-firm-survive

Where is SRNE? https://www.wsj.com/articles/judge-declines-to-dismiss-sorrento-therapeutics-bankruptcy-case-8321bd69

And here's an interesting article on the background in which Mesoblast Ltd has been operating for the last few years, IMO: https://www.fiercebiotech.com/special-reports/biotech-bankruptcies-break-10-year-record-2023

I give the MSB Board of Directors credit for observing, consistent with confidentiality and competitive secrecy, their duties to the MSB shareholder base as a whole, especially ASX/ NASDAQ disclosure after acting on considered legal and regulatory advice, etc.

I'm OK with how things are playing out. I've got other stuff to do.

I don't do rockets to the moon rubbish & I don't expect anyone to hold my hand.

And I absolutely don't trust analysts in a volatile manipulable market to value a pre-breakeven biotech like MSB properly.

Cheers,
GLTA(LT)H